In what neurologists are calling the most significant advance in Alzheimer’s disease treatment in two decades, the U.S. Food and Drug Administration today granted full approval to donanemab-azbt (Kisunla) — a monoclonal antibody therapy that demonstrated a 47% slowing of cognitive and functional decline in patients with early symptomatic Alzheimer’s disease.
What the Clinical Trial Showed
The landmark TRAILBLAZER-ALZ 2 trial enrolled 1,736 participants with early symptomatic Alzheimer’s disease and confirmed amyloid pathology. Over 76 weeks, patients receiving donanemab showed dramatically slower progression on the integrated Alzheimer’s Disease Rating Scale (iADRS) compared to those on placebo.
Among patients with low to medium baseline tau levels — considered the most treatment-responsive subgroup — the drug slowed decline by 60% on the primary endpoint. Participants also showed a 40% reduction in the risk of progressing to the next stage of the disease.
“These results represent a paradigm shift. We are no longer talking about symptomatic management — we are for the first time meaningfully altering the disease course in Alzheimer’s patients.”
— Dr. Liana Apostolova, Indiana University School of Medicine, lead trial investigator
How the Drug Works
Donanemab targets N3pG amyloid — a modified form of the amyloid-beta protein that accumulates in the brains of people with Alzheimer’s disease. Unlike earlier anti-amyloid therapies, the drug is designed to clear existing plaques rather than simply slow their accumulation.
One of the trial’s most striking findings: a significant proportion of treated patients achieved amyloid clearance to sub-threshold levels, after which dosing could be paused. This “stop when clear” approach offers a distinct advantage over continuous infusion therapies.
Safety Profile and ARIA Risk
The drug’s approval comes with a Risk Evaluation and Mitigation Strategy (REMS) program due to the risk of amyloid-related imaging abnormalities (ARIA) — brain swelling and microhemorrhages detected on MRI. In the trial, 24% of participants developed ARIA-E (edema), with approximately 6% experiencing symptomatic episodes.
The FDA requires baseline and follow-up MRI screening, and the drug is contraindicated in carriers of two copies of the APOE4 gene variant, who face significantly elevated ARIA risk.
Who Is Eligible?
The approval covers adults with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease with confirmed amyloid pathology — typically verified through PET scan or cerebrospinal fluid biomarker testing. Genetic testing for APOE4 status is recommended before initiating treatment.
Access and Cost Concerns
The drug’s list price is expected to be approximately $32,000 per year. Medicare has indicated it will cover the therapy for eligible beneficiaries, though neurologists expect significant demand challenges as the healthcare system scales up the diagnostic infrastructure required — particularly PET imaging — to identify appropriate candidates.
“We have the drug,” said Dr. Maria Carrillo, Chief Science Officer of the Alzheimer’s Association. “Now we need the ecosystem to deploy it equitably.”
What This Means for Patients
Approximately 6.7 million Americans are currently living with Alzheimer’s disease. Experts estimate that 1–2 million may be candidates for this therapy based on eligibility criteria. Patient advocacy groups are urging CMS to accelerate coverage determinations and expand access to tau PET imaging at community hospitals.
For early-stage patients and their families, the approval marks the beginning of a new era — one in which Alzheimer’s disease, long considered a one-way door, may finally be slowed.
Leave a Reply